Gemcitabine HCL Market Size is Expected to Reach US$ 1.3 Billion and Growing at 7.8% CAGR by 2031 due to Rise in Cancer Awareness

According to the report, the global gemcitabine HCl market is projected to reach a value of over US$ 1.3 Bn by 2031, expanding at a CAGR of nearly 7.8% from 2022 to 2031. Initiatives by key players, and the growing number of patient support organizations and governmental & healthcare agencies to spread awareness regarding cancer is projected to drive the global gemcitabine HCl market. Technical advancements in the manufacturing of generic drugs have also led to an increase in the demand for gemcitabine HCl, which is expected to propel the global gemcitabine HCl market in the near future.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐬𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 (𝐔𝐬𝐞 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐌𝐚𝐢𝐥 𝐈𝐝 𝐟𝐨𝐫 𝐐𝐮𝐢𝐜𝐤 𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐞) - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=67622

𝐆𝐞𝐦𝐜𝐢𝐭𝐚𝐛𝐢𝐧𝐞 𝐇𝐂𝐥 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰

• The gemcitabine HCl market report offers exhaustive segmentation of the global market based on type, application, and end user. In terms of type, the gemcitabine HCl market has been segmented into branded and generic. The generic segment held a major share in the gemcitabine HCl market in 2018. Low cost, similar efficacy, and increase in the demand for generic drugs are the factors driving this segment in the global gemcitabine HCl market.
• Based on application, the global gemcitabine HCl market has been classified into pancreatic cancer, breast cancer, ovarian cancer, non-small-cell lung carcinoma (NSCLC), and others. The pancreatic cancer segment held a leading market share in 2018, owing to increased incidences of this disease. Pancreatic cancer usually affects the geriatric population. Increase in the geriatric population is one of the factors fueling the growth of this segment in the global gemcitabine HCl market.
• In terms of end user, the global gemcitabine HCl market has been divided into hospitals, cancer centers, and others. The hospitals segment is anticipated to grow at a rapid pace in the next few years. The adoption of healthcare information systems in hospitals is rising in Asia Pacific due to an increase in the number of private sector hospitals in the region. This, in turn, is likely propel the gemcitabine HCl market in the next few years.
• Geographically, the global gemcitabine HCl market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, North America and Asia Pacific gemcitabine HCl markets are anticipated to drive global demand. The gemcitabine HCl market in North America is expected to expand at a high CAGR from 2019 to 2027. This is attributed to the adoption of cost-effective genetic drugs, expiry of patented products, proper guidelines for the manufactures of biosimilars, and the presence of a large number of players in the generics market in the region.
• The demand for cost-effective generic cancer drugs is rising, especially in emerging countries such as China, India, and Brazil. This is due to the increase in the incidences of cancer and a surge in the acceptance of generic drugs in the global gemcitabine HCl market.

𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐒𝐞𝐠𝐦𝐞𝐧𝐭 𝐄𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐆𝐫𝐨𝐰 𝐚𝐭 𝐚 𝐑𝐚𝐩𝐢𝐝 𝐏𝐚𝐜𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐆𝐞𝐦𝐜𝐢𝐭𝐚𝐛𝐢𝐧𝐞 𝐇𝐂𝐥 𝐌𝐚𝐫𝐤𝐞𝐭

• The report offers exhaustive segmentation of the global gemcitabine HCl market based on type, application, and end user. In terms of type, the gemcitabine HCl market has been segmented into generic and branded.
• The generic segment held a major share in the gemcitabine HCl market in 2018. This segment is likely to grow at a rapid pace in the next few years, attributed to the strong pipeline of generic gemcitabine HCl drugs. In order to market a generic drug, a company needs to file an Abbreviated New Drug Application (ANDA). An ANDA approval implies that the generic drug is comparable to the original drug in terms of strength, dosage form and quality, route of administration, performance, characteristics, and intended use.
• However, companies cannot manufacture a generic unless the patent of a drug expires. After the patent loss of Gemzar in 2010, several generics have entered the gemcitabine HCl market. The demand for low-cost substitutes of gemcitabine HCl is high in low- and middle-income countries in the Asia Pacific, Africa, and Latin America gemcitabine HCl markets.
• This has increased the number of gemcitabine API manufacturers, since pharmaceutical drug manufacturers do not have enough in-house capacity to meet the demand.

𝐁𝐮𝐲 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 | 𝐈𝐦𝐦𝐞𝐝𝐢𝐚𝐭𝐞 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐚𝐭 - https://www.transparencymarketresearch.com/checkout.php?rep_id=67622<ype=S

𝐏𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐜 𝐂𝐚𝐧𝐜𝐞𝐫 & 𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐬 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐭𝐨 𝐂𝐚𝐩𝐭𝐮𝐫𝐞 𝐏𝐫𝐨𝐦𝐢𝐧𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐡𝐚𝐫𝐞𝐬

• The pancreatic cancer segment held a major market share in 2018, owing to the rise in incidences of pancreatic cancer. According to WHO, there will be nearly 638,647 new cases of pancreatic cancer in 2030, as against 458,918 in 2018.
• This increase in the number of cases is primarily due to the increasing geriatric population, and the associated risk factors becoming increasingly common among the population. This is expected to drive the global gemcitabine HCl market in the new few years.
• The hospitals segment is expected to grow at a rapid pace in the next few years. Hospitals provide low-cost treatment to all citizens across the globe.
• Strategic collaborations with hospitals for cancer research studies on several hundred patients with a variety of cancer types have helped companies come up with novel drugs and therapeutic treatments.
• The hospital infrastructure in emerging countries is developing at a significant pace, as various regional and national governments (for example Saudi Arabia) are encouraging private players to enter the healthcare services sector.

𝐀𝐬𝐢𝐚 𝐏𝐚𝐜𝐢𝐟𝐢𝐜 𝐆𝐞𝐦𝐜𝐢𝐭𝐚𝐛𝐢𝐧𝐞 𝐇𝐂𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 𝐄𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐄𝐱𝐩𝐚𝐧𝐝 𝐚𝐭 𝐚 𝐇𝐢𝐠𝐡 𝐂𝐀𝐆𝐑

• North America is likely to be a prominent region in the global gemcitabine HCl market during the forecast period. Easy adoption of new products, presence of key players, and favorable reimbursement policies are attributed to the region's dominance in the global gemcitabine HCl market. The gemcitabine HCl markets in Europe and Asia Pacific are also projected to grow at a rapid pace from 2019 to 2027.
• The gemcitabine HCl market in these regions are anticipated to be driven by the rise in the demand for cost-effective generic cancer drugs, especially in emerging countries such as China, India, and Brazil, due to an increase in the incidences of cancer and a surge in the acceptance of generic drugs. Additionally, India- and China-based drug manufacturers have a strong presence in the global gemcitabine HCl market. Gemcitabine API manufacturers in India have been investing to comply with U.S. FDA regulations and to win contracts from U.S.-based companies, and have been filing DMF applications. This is expected to boost the global gemcitabine HCl market in the coming years.
• Additionally, initiatives by key players, patient support organizations, and governmental & healthcare agencies to spread awareness about cancer are expected to boost the growth of the gemcitabine HCl market in these regions. Technical advancements in the manufacture of generic drugs have also led to an increase in the demand for gemcitabine HCl, which is expected to propel the global gemcitabine HCl market in the near future.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐜𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=67622

𝐆𝐞𝐦𝐜𝐢𝐭𝐚𝐛𝐢𝐧𝐞 𝐇𝐂𝐥 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:

• Major players operating in the global gemcitabine HCl market include Teva Pharmaceutical Industries Ltd., Lupin Ltd., Sanofi, Biocon. Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd., Mylan N.V., GlaxoSmithKline plc, and AstraZeneca plc.
• Launch of new products, focus on development of technologically-advanced products by companies, and product approvals are expected to drive the global gemcitabine HCl market during the forecast period.

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 -

𝐏𝐥𝐚𝐬𝐦𝐚 𝐏𝐫𝐨𝐭𝐞𝐢𝐧 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭- https://www.prnewswire.com/news-releases/firms-in-plasma-protein-therapeutics-market-tap-into-vast-demand-for-immunoglobulins-ig---tmr-study-301670018.html

𝐕𝐢𝐫𝐚𝐥 𝐕𝐞𝐜𝐭𝐨𝐫 & 𝐏𝐥𝐚𝐬𝐦𝐢𝐝 𝐃𝐍𝐀 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭- https://www.prnewswire.com/news-releases/viral-vector--plasmid-dna-manufacturing-market-global-industry-analysis-tmr-study-301671517.html

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.